Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SCLEROSOL vs BYQLOVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of blood vessels and causing inflammation, thrombosis, and fibrosis, leading to obliteration of the injected vein.
BYQLOVI (revumenib) is a menin inhibitor that binds to the menin protein, blocking its interaction with mixed lineage leukemia (MLL) fusion proteins and thus inhibiting leukemogenesis.
Treatment of uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Treatment of small varicose veins
Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation in adults and pediatric patients 1 year and older
0.5-5 m L of 5% solution administered by intrapleural injection once daily for up to 3 days.
BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is administered orally as a single tablet (50/200/25 mg) once daily with or without food.
60-90 minutes (clinical context: rapid elimination requires multiple daily dosing for maintenance of effect)
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; prolonged in renal impairment.
Sodium tetradecyl sulfate is a small molecule that is not significantly metabolized; it is eliminated primarily via renal excretion.
Primarily metabolized by CYP3A4 and CYP2D6.
Primarily renal (80-90% unchanged), minimal biliary/fecal (5-10%)
Renal excretion of unchanged drug accounts for approximately 95% of elimination; fecal excretion is minimal (<5%).
20-30% (primarily to albumin)
Approximately 85% bound to serum albumin.
0.3-0.5 L/kg (clinical meaning: moderate distribution, mainly in extracellular fluid)
Volume of distribution is about 0.6 L/kg, indicating distribution into total body water.
Oral: 10-20% (first-pass effect); subcutaneous: 70-80%; intramuscular: 75-85%; intravenous: 100%
Oral bioavailability is approximately 80% (range 75–85%) under fasting conditions; food may reduce absorption.
No specific dose adjustment required; use with caution in severe renal impairment.
Contraindicated in patients with estimated creatinine clearance (Cr Cl) <30 m L/min. No dose adjustment required for Cr Cl ≥30 m L/min.
No specific dose adjustment required for Child-Pugh A or B; avoid in Child-Pugh C due to risk of toxicity.
Not recommended in patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment required for mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
Not recommended for pediatric use due to lack of safety and efficacy data.
For adolescents aged ≥12 years and weighing ≥35 kg, administer one tablet (50/200/25 mg) orally once daily. Safety and efficacy not established in pediatric patients <12 years or <35 kg.
No specific dose adjustment; monitor for pleural irritation and systemic effects due to increased sensitivity.
No specific dose adjustment recommended in elderly patients. Monitor renal function due to age-related decline.
There is no FDA black box warning for SCLEROSOL.
No FDA boxed warning reported.
Anaphylactic shock and allergic reactions,Arterial injection causing tissue necrosis,Deep vein thrombosis and pulmonary embolism,Intra-arterial injection leading to severe ischemia,Risk of anaphylaxis in patients with multiple allergies
Differentiation syndrome, which may be life-threatening or fatal; if suspected, initiate corticosteroids and hemodynamic monitoring.,QTc interval prolongation; monitor electrolytes and electrocardiograms.,Embryo-fetal toxicity.
Known hypersensitivity to sodium tetradecyl sulfate,Acute thromboembolic disease,Severe peripheral arterial disease,Incompetent perforating veins without treatment of underlying reflux,Uncontrolled systemic disease (e.g., diabetes, hyperthyroidism),Local infection at the injection site,Bedridden patients
None reported.
No known food interactions. Maintain adequate hydration. Avoid alcohol for 24 hours post-treatment to minimize vasodilation.
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit as they inhibit CYP3A4 and can increase drug levels, leading to toxicity. No other known food interactions. Take with or without food, but consistent timing and fat content is recommended to maintain stable exposure.
FDA Pregnancy Category C. Sclerosol (talc) is not absorbed systemically when used intrapleurally; however, inadvertent intravenous administration or systemic absorption may occur. Animal reproduction studies have not been conducted. Inadvertent maternal exposure could theoretically cause fetal harm. Use only if clearly needed during pregnancy; avoid during first trimester if possible.
BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is contraindicated in pregnancy due to risk of neural tube defects (NTDs) observed with dolutegravir-containing regimens in first trimester exposure. In animal studies, no evidence of teratogenicity at clinically relevant exposures. Human data: insufficient for risk assessment; case reports of NTDs with bictegravir insufficient to rule out. First trimester: potential for NTDs, avoid unless benefit outweighs risk. Second/third trimester: limited data, no specific fetal risks identified, but use alternative if possible.
No data on excretion into breast milk. Talc is not absorbed systemically when used intrapleurally, but trace amounts may enter milk. Due to lack of studies, caution is advised. The milk-to-plasma ratio is unknown. Consider discontinuing breastfeeding or alternative agents.
Breastfeeding not recommended during BYQLOVI therapy due to potential for HIV-1 transmission via breast milk and unknown effects in infants. Bictegravir excretion into human milk unknown; emtricitabine: M/P ratio ~0.6; tenofovir alafenamide: M/P ratio ~0.3 (tenofovir). Limited data: low levels may be excreted. HIV-positive mothers should not breastfeed to avoid transmission.
No pharmacokinetic changes expected as systemic absorption is negligible. Standard intrapleural dosing (e.g., 2-10 g in 50-250 m L saline) may be used, but consider gestation-related pleural space changes. No dose adjustment recommended, but use lowest effective dose to minimize complications.
No specific dosing adjustments recommended during pregnancy due to limited data. Pharmacokinetic studies in pregnancy are lacking. Bictegravir AUC may decrease in second and third trimester; clinical relevance unknown. Consider alternative antiretroviral regimens with established safety data in pregnancy (e.g., dolutegravir plus emtricitabine/tenofovir disoproxil fumarate).
SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent used for varicose veins and telangiectasias. Avoid extravasation; tissue necrosis may occur. Use caution in patients with thrombophlebitis or hypercoagulable states. Max dose per session: 10 m L of 3% solution. Contraindicated in pregnancy and known allergy to the drug.
BYQLOVI (bruton tyrosine kinase inhibitor) is indicated for chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia. Monitor for atrial fibrillation, hypertension, and bleeding risk. Administer with a full glass of water and do not crush or open capsules. Dose reduction may be needed with strong CYP3A4 inhibitors. Avoid concurrent use with warfarin or other anticoagulants if possible.
You may experience a burning sensation at the injection site that lasts a few minutes.,Avoid strenuous activity and prolonged standing for 24-48 hours after treatment.,Wear compression stockings as directed to improve outcomes and reduce side effects.,Report any signs of infection, severe pain, or leg swelling to your doctor immediately.,Multiple sessions may be needed for complete vein closure.
Take exactly as prescribed, with a full glass of water.,Do not open, break, or chew the capsules; swallow whole.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit while on this medication.,Report any signs of bleeding (e.g., unusual bruising, black stools) or irregular heartbeat immediately.,Avoid activities that may cause injury due to increased bleeding risk.,Use effective contraception during treatment and for at least 1 month after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SCLEROSOL vs BYQLOVI, answered by our medical review team.
SCLEROSOL is a Sclerosing Agent that works by SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of blood vessels and causing inflammation, thrombosis, and fibrosis, leading to obliteration of the injected vein.. BYQLOVI is a Topical Retinoid that works by BYQLOVI (revumenib) is a menin inhibitor that binds to the menin protein, blocking its interaction with mixed lineage leukemia (MLL) fusion proteins and thus inhibiting leukemogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SCLEROSOL and BYQLOVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SCLEROSOL is: 0.5-5 m L of 5% solution administered by intrapleural injection once daily for up to 3 days.. The standard adult dose of BYQLOVI is: BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is administered orally as a single tablet (50/200/25 mg) once daily with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SCLEROSOL and BYQLOVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SCLEROSOL is classified as Category C. FDA Pregnancy Category C. Sclerosol (talc) is not absorbed systemically when used intrapleurally; however, inadvertent intravenous administration or systemic absorption may occur. . BYQLOVI is classified as Category C. BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is contraindicated in pregnancy due to risk of neural tube defects (NTDs) observed with dolutegravir-containing regimens i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.